Methotrexaat Focus Care (Methotrexate)

Methotrexate blocks dihydrofolate reductase, a key enzyme in folate metabolism. This inhibition reduces the formation of tetrahydrofolate, limiting the synthesis of nucleotides required for DNA replication. Consequently, rapidly dividing cells such as immune cells and malignant cells experience reduced proliferation.

The specific dose of Methotrexaat Focus Care is determined by the prescribing clinician based on the patient’s condition, disease severity, renal and hepatic function, and other individual factors. Healthcare professionals tailor the regimen to achieve optimal therapeutic effect while minimizing risk.

Methotrexaat Focus Care is classified as Pregnancy Category X, indicating it is contraindicated in pregnancy because of a high risk of fetal harm. It is also not recommended while breastfeeding, as methotrexate can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Methotrexaat Focus Care belongs to the antimetabolite class of DMARDs, offering a well‑established efficacy profile for rheumatoid arthritis and psoriasis. Compared with biologic DMARDs, methotrexate is oral, less costly, and has a broader range of oncologic indications, though it may require more laboratory monitoring for toxicity.

Methotrexaat Focus Care should be stored at temperatures below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Methotrexaat Focus Care is supplied as an oral formulation. Patients take the tablet with water, usually once weekly, unless the prescriber advises a different schedule. It may be taken with or without food, but consistent administration helps maintain stable drug levels.

The most serious risks include severe liver toxicity, bone‑marrow suppression leading to pancytopenia, pulmonary fibrosis, and life‑threatening infections due to immunosuppression. Patients should be monitored regularly for liver enzymes, blood counts, and respiratory symptoms, and any alarming signs should prompt immediate medical evaluation.

Methotrexaat Focus Care is contraindicated in pregnant women, individuals with severe renal or hepatic impairment, and patients with known hypersensitivity to methotrexate or any component of the formulation. It should also be avoided in patients receiving live vaccines or those with uncontrolled infections.